+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Crohns disease is a long-lasting condition causing severe inflammation in the digestive tract, mainly affecting the bowels. Symptoms include belly pain, diarrhea, tiredness, and weight loss. This study evaluates targeted therapies for adults with moderate to severe Crohns disease, aiming to understand their effectiveness and side effects. The trial is a Phase 2a randomized platform study involving about 590 participants worldwide. Participants will be randomly assigned to receive one of several treatments risankizumab, trosunilimab, lutikizumab, or ABBV-8736, administered either by injection under the skin or infusion into the vein. Some groups receive combination therapies involving different doses and delivery methods. A long-term extension allows risankizumab monotherapy for up to 72 weeks. Treatments are given at hospitals or clinics in scheduled visits. During the study, participants attend regular visits for medical assessments including blood tests, endoscopies, and questionnaires. Researchers monitor treatment effects, side effects, and disease activity using tools like endoscopic remission and clinical remission scores. Safety and adverse events are tracked up to approximately 96 weeks. Participants keep daily diaries and complete questionnaires to aid data collection.

Age: 18Years - 75YearsAll GendersPhase 2
255 locations
R

Actively Recruiting

Neovascular age-related macular degeneration nAMD, often called wet AMD, involves abnormal growth of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. This research aims to evaluate the safety and effectiveness of Surabgene Lomparvovec, an investigational gene therapy, in adults aged 50 and older who have been previously treated for nAMD. Approximately 561 participants will be enrolled globally and randomized into three groups to compare different treatments. Participants will be assigned to one of three groups two groups receive a single subretinal injection of Surabgene Lomparvovec at different doses, and the third group receives Ranibizumab injections as needed throughout the study. Ranibizumab is given as an intravitreal injection into the jelly-like tissue inside the eye, while Surabgene Lomparvovec is delivered beneath the retina. The studys assessment period begins two weeks before randomization and follows participants for up to five years. During the study, participants will attend monthly visits at a hospital or clinic where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted to evaluate treatment effects. Researchers will track the annual rate of anti-VEGF injections and monitor adverse events over five years, along with changes in visual acuity. The study is designed to assess long-term treatment burden, safety, and preservation of vision in a real-world context.

Age: 50Years +All GendersPhase 3
138 locations
C

Actively Recruiting

Researchers are comparing two methods of restoring blood flow to the heartpercutaneous coronary intervention PCI and coronary artery bypass grafting CABGin patients with multivessel or left main coronary artery disease and reduced heart pumping function known as ischemic left ventricular dysfunction. This international, randomized trial aims to determine which method better reduces death, stroke, heart attack, urgent repeat procedures, or heart failure hospitalizations over a median follow-up of five years. The study addresses the current lack of strong evidence comparing these modern revascularization approaches in this vulnerable patient group. Participants will be randomly assigned to receive either PCI or CABG, with treatments planned by a specialized Heart Team including cardiologists and cardiac surgeons. PCI will follow contemporary best practices like using drug-eluting stents and advanced imaging. CABG will be tailored based on individual anatomy and health, with specific surgical techniques recommended. Initial revascularization is expected within two weeks of randomization, and staged PCI procedures within 90 days. Enrollment spans three years, with total study duration of seven years and median follow-up of five years. During the study, participants will undergo regular assessments including clinical evaluations, imaging, and monitoring for adverse events. The main outcomes measured include a composite of death, stroke, heart attack, urgent repeat procedures, and heart failure readmissions. Secondary outcomes track early risks, hospitalizations, and patient-reported health status throughout the follow-up. Safety and efficacy data will be collected up to the studys completion, providing comprehensive insights into treatment impacts over time.

Age: 18Years +All GendersPhase Not Applicable
46 locations